Last updated on February 2018

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)


Brief description of study

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.

Investigator's sites: 40 sites in Germany.

Primary objectives:

  • Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
  • Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
  • Documentation of treatment strategy

Detailed Study Description

see brief summary

Clinical Study Identifier: NCT03188874

Find a site near you

Start Over

Klinikum Frankfurt (Oder) GmbH

Frankfurt an der Oder, Germany
  Connect »

Westpfalz-Klinikum GmbH

Kaiserslautern, Germany
  Connect »